Neumora Therapeutics Inc. came out of stealth mode on 7 October with more than $500m in initial financing to fund its platform for the discovery and development of precision medicines in neurological and neuropsychiatric diseases, as well as an initial pipeline of eight preclinical and clinical product candidates. The platform combines biological insights with data science capabilities to develop therapies for the patient subpopulations most likely to respond to treatment.
Amgen, Inc. supplied $100m of the two-year-old start-up’s new funding under a collaboration agreement also announced on 7 October...






